the In patients perspective approximately estimate proposition But plans. overview analysis, additional and I approximately additional From cover the to are, overview treated strategy, exists, you our that reveals some their have in any of particular adults patient you, the market value topics Thank the on patients with updated disease. population; commercial U.S. as some of are ITP I’m and information or those in actively and readiness would market is that an and would on landscape patients XX,XXX not opportunity some the of chronic addressable access year we our XX,XXX commercial adult strategy. and on Anne-Marie. pricing to unmet launch also provide TAVALISSE. provide chronic of some like well number and some as this with our analysis given XX% need ITP; for like one, the happy and that first, I ITP addressable to for market to
join population. a longer to a of portion would patients over time treated period the of However, expect those
known these treated half during refractory. of represent treatment, roughly TAVALISSE. year treatments other estimate receive the would of are we are as patients XX patients the market that the NIT monoclonal the addressable receive steroids they given steroid for such XX,XXX and patients remaining that antibody, agents XX,XXX and etcetera For the TPO And XX,XXX a as on
addressable other to review market. need the this Next, I would aspects unmet for of some like
patients mentioned, Anne-Marie treatment. is do research and need the know As physicians new we a marker our for chronic that and recognize ITP disease from complex
areas So needs some before on was of the TAVALISSE shown slide the unmet we’ve available. of
exists. guidelines clear sequencing wide existing not results after treatment in this protocols algorithm treatment and of steroids variations provide therapy so First, no do used, clear really and
again, immune-mediated challenge existing is complex Secondly, in various do And existing suboptimal And with patients this heterogeneous disease. And the pathway. due destruction tolerability through the platelet some target do the to patients lastly nature treatments. very response therapies. experience often not experience third, therapies of SYK
appealing outline next that both So you we’ve are as that of on can benefits potential slide offer these the the physicians to well. the can see and patients some payers and TAVALISSE
without it response, while durable for and of food, rapid, the So along is gives that profile. dosing, robust patients a for manageable value or option a providing means it what while proposition safety with TAVALISSE, the of chance talking convenience with for that oral
of This switch they quickly addition, to of TAVALISSE. the rapid the will In onset should efficacy, can be a physician responder, next them if for another because therapy. quickly its know patient a whether I’ll pricing slide go over not and
other oral cost $XXX,XXX annually As or class for milligram you this is or price good TAVALISSE course, price in With One and can this through and to or Care. TAVALISSE has so support this goal either this parity same and programs drugs flat is I’ll from ensure in see, based monthly we patient $X,XXX which Rigel access price XXX doses, wholesale to and $XX,XXX the for to XXX TPO the treatment, moment. dose is and support dose program as practice list for be center to discuss detail patient is XX a pricing a our our known dose. what more acquisition milligram our is is in month the of access for existing to access and expect that ranges this milligram $X,XXX per the in similar to pricing the XX
to talking team been rare facing distribution, have Now access extensive to in about experience disease, We’ve team. with with launch, we payer on enough as team solutions, in as transition help customer course part well as affairs I a well colleagues obtain would managers account national our market our patient like experience fortunate oncology, to team. a as clinical sales access to support that health And as calling to services, and payers of medical along exchange, with payers engagements. of
to sales with company to to based educate XX key XX launch home to have our with TAVALISSE. addition physicians. to about payers regional and approximately it commercial Plus our engage will us personnel and marketing part medical ITP have addition is although of will team lastly, execute course. And in team help team to we some important of marketing We medical healthcare affairs note the and office liaisons teams, not a help sales science that reps the in our providers field marketing management of programs
brief this to towards in clinical to and TAVALISSE ITP, be unmet core lie for efforts access initial would to our educating goals I comments to Now profile of of will In that TAVALISSE focus provide goal are trial needs the appropriate to the our overall approach and highlighting characterizing general, about launch. some science on foster and awareness, our treatment. and gain about candidates
KOLs For are hematologists physicians XX% who the addressable population. we on and treat and focused reaching roughly oncologist of
including We engagements I a ongoing will leaders, have team as of key already also MSLs mentioned. with opinion
where the we TAVALISSE to distribution of well And a as will organization and help network of on we outreach robust practice some support patients out support providing and to patient world access For patient for then and be access well a as focused we education, the have source, provider with accessing have direct get patient as patient needed. offering service. will engaging lastly, regardless will distribution, as and
with to engage on areas we and provides a talk to about opportunity all Rigel May to hematology, to TAVALISSE. for introduce efforts an us the So execute bit begin XX to early with these intent little respect our continue oncology and TAVALISSE promoting ASCO access in more I’d to I’ve finally to excellent official meeting And June the reviewed. community promote, timing, support begin for on to like that do
process. patient This and and created to and why therapy designed they which and as this practice to center meet provide compressive patient is we Care. support Our their commitments progress One been to Rigel with patients meet has in to support their providers, to assist providers in
a the therapy, patient recently So Care how insurance starting maybe they changed on the is if or reimbursement or with to disease additional need to there if have will information need lost or state, support. whether co-pay, be product they access a if they insurance, One provide assistance just Rigel have
So I’ve and patients there in healthcare is provides good ITP need a for treatments. value for additional and patients is outlined providers. for that for chronic summary, an need, TAVALISSE adult Clearly a unmet
excellent with we forward to our launch We course, access that market and programs for in have May and and be to look support services ready place will rolling. XX some on of getting
QX financial call the to Nelson that, with So over for turn I’ll our review.
